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Summary
 
Apoptosis induced by T cell receptor (TCR) triggering in T lymphocytes involves activation of
cysteine proteases of the caspase family through their proteolytic processing. Caspase-3 cleav-
age was also reported during T cell stimulation in the absence of apoptosis, although the physi-
ological relevance of this response remains unclear. We show here that the caspase inhibitor
benzyloxycarbonyl (Cbz)-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD) blocks proliferation,
major histocompatibility complex class II expression, and blastic transformation during stimula-
tion of peripheral blood lymphocytes. Moreover, T cell activation triggers the selective processing
and activation of downstream caspases (caspase-3, -6, and -7), but not caspase-1, -2, or -4, as dem-
onstrated even in intact cells using a cell-permeable fluorescent substrate. Caspase-3 processing oc-
curs in different T cell subsets (CD4
 
1
 
, CD8
 
1
 
, CD45RA
 
1
 
, and CD45RO
 
1
 
), and in activated B
lymphocytes. The pathway leading to caspase activation involves death receptors and caspase-8,
which is also processed after TCR triggering, but not caspase-9, which remains as a proenzyme.
Most importantly, caspase activity results in a selective substrate specificity, since poly(ADP-ribose)
polymerase (PARP), lamin B, and Wee1 kinase, but not DNA fragmentation factor (DFF45) or
replication factor C (RFC140), are processed. Caspase and substrate processing occur in nonapop-
totic lymphocytes. Thus, caspase activation is an early and physiological response in viable, stimu-
lated lymphocytes, and appears to be involved in early steps of lymphocyte activation.
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C
 
ysteine proteases of the IL-1
 
b
 
–converting enzyme (ICE)
family (caspases) are critical executioners of apoptosis
in several mammalian cell death pathways (1). At present,
14 human and murine caspases have been isolated, and the
exact role of each one during apoptosis has yet to be fully
characterized. Caspases are synthesized as inactive precursors
that require proteolytic conversion to become active pro-
teases. For instance, during apoptosis triggered by TCR
cross-linking in T lymphocytes, the 32-kD caspase-3 proen-
zyme is first cleaved to release fragments of 12 and 20 kD.
Removal of the 3-kD propeptide from the p20 generates the
p17 form associated with caspase-3 activity and apoptosis (2,
3). Caspase-3 cleavage also occurs
 
 
 
in vivo during negative
selection of thymocytes through TCR signaling, where only
the p17 is detected (4, 5). This mechanism prevails in a wide
variety of cellular systems, and is triggered upon induction of
apoptosis by several exogenous stimuli (1).
 
The current model suggests that after apoptotic stimulation,
activation of “upstream” caspases containing a large prodomain
such as caspase-8, -2, or -9 leads to the proteolytic cleavage
of “downstream” caspases (caspase-3, -6, and -7), which me-
 
diate the apoptotic response (1, 6). Another caspase subfamily
including caspase-1, -5, -11, -12, and -13 is essentially involved
in cytokine maturation, and does not seem to play a critical
role during apoptosis. Caspase activity results in the cleavage
of several cellular proteins, which leads to the apoptotic re-
sponse (for a review, see reference 7). These substrates in-
clude structural proteins such as gelsolin (8), proteins involved
 
in DNA repair, such as poly(ADP-ribose) polymerase (PARP)
 
1
 
1
 
Abbreviations used in this paper:
 
 AV, annexin V; Cdc2, cell division control 2;
DFF45, the 45-kd subunit of DNA fragmentation factor; Extra-HRP, HRP–
conjugated extravidin; FADD, Fas-associated death domain protein; HRP,
horseradish peroxidase; IAP, inhibitor of apoptosis; PARP, poly(ADP-ribose)
polymerase; PI, propidium iodide; RFC140, the 140-kD subunit of replica-
tion factor C; SAC, 
 
Staphylococcus aureus
 
 Cowan cell extracts; zVAD, benzyl-
oxycarbonyl (Cbz)-Val-Ala-Asp(OMe)-fluoromethylketone.
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(2, 9) or DNA-dependent protein kinase (DNA-PK [10]),
and proteins involved in cell cycle regulation, such as the
140-kD subunit of replication factor C (RFC140 [11]),
mouse double minute 2 (MDM2 [12]), or the cell division
control 2 (Cdc2) kinase Wee1 (13). A critical substrate for
caspase-3 during apoptosis is the 45-kD subunit of DNA
fragmentation factor (DFF45) that once cleaved by caspase-3
activates DNA fragmentation by releasing the caspase-acti-
vated DNase (14–16).
Surprisingly, caspase-3 processing and activity have been
observed in the absence of apoptosis after polyclonal activa-
tion of PBMCs, and in the absence of DNA fragmentation
(17, 18). However, there is no evidence yet for a role of
caspases during T cell activation, and a recent report sug-
gested that the observed caspase processing was due to the
production of granzyme B by CD8
 
1
 
 activated cells and ar-
tifactual release during cell lysis of PBMCs (19). Interestingly,
such a role for caspases in T cell activation is indirectly sup-
ported by several recent observations. Indeed, interference
with pathways leading to caspase processing, as in Fas-asso-
ciated death domain protein (FADD) knockout, FADD
dominant negative, or Bcl-2 transgenic mice, results in
impaired mature T cell proliferation (20–23). Moreover,
overexpression of Bcl-2 also delays the reentry of resting
NIH 3T3 cells into cell cycle (24). These data suggest that
inactivation of pathways leading to caspase activity results
in reduced cell cycle progression in primary T lymphocytes
and in cell lines.
In this study, we have investigated whether caspase pro-
cessing was a physiological response after TCR triggering.
We show that a caspase inhibitor blocks T cell activation,
that caspase-3 and other downstream caspases are processed
in stimulated lymphocytes, and that a selective cleavage of
caspase substrates occurs in viable and proliferating cells.
These results show that caspase activation is a physiological
response to TCR triggering, and indicate that this enzy-
matic cascade is not only involved in induction of cell
death, but might also be involved in the early steps leading
to lymphocyte proliferation.
 
Materials and Methods
 
Reagents and Antibodies. 
 
The broad spectrum benzyloxycar-
bonyl (Cbz)-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD), the
caspase-3–like Cbz-Asp-Glu-Val-Asp(OMe)-fluoromethylketone
(zDEVD) or caspase-8–like Cbz-Ileu-Glu-Thr-Asp(OMe)-fluoro-
methylketone (zIETD) caspase inhibitors, and the biotinylated
zVAD were purchased from Enzyme Systems Products. IL-2 was
obtained from the National Institutes of Health AIDS Research
and Reference Reagent Program, and PHA from Murex Diag-
nostics. 
 
Staphylococcus aureus
 
 Cowan fixed cells (SAC) were purchased
from Calbiochem. Rabbit antiserum against caspase-3 was generated
as described previously (5). The anti–caspase-8 and anti-DFF45 an-
tisera are rabbit polyclonal antibodies generated in the laboratory
against the p18 of caspase-8 and the full-length DFF45, respec-
tively. The anti-PARP antiserum, a second anti–caspase-8 serum,
the anti-lamin B, and anti-Fas (M3) mAbs were gifts from Dr. G.
Poirier (Centre Hospitalier de l’Université Laval, Québec, Can-
ada), Dr. M.E. Peter (German Cancer Research Center, Heidel-
 
berg, Germany), Dr. R. Bertrand (Centre de Recherche du Centre
Hospitalier de l’Université de Montréal), and Dr. D. Lynch (Immu-
nex Corp., Seattle, WA), respectively. Dr. D.W. Nicholson (Merck
Frosst, Kirkland, Canada) provided antisera against caspase-1, -6, -7,
and -9. The mAbs against caspase-2, caspase-4, and Wee1 were
purchased from Transduction Laboratories, Santa Cruz Biotechnol-
ogy, and StressGen Biotechnologies Corp., respectively. The anti-
CD3 was produced and purified from the OKT3 clone (American
Type Culture Collection).
 
PBMC Isolation and Proliferation Assay. 
 
PBMCs were purified
by Ficoll-Hypaque and resuspended in 10% FCS-RPMI medium
(GIBCO BRL). To monitor proliferation, 10
 
5
 
 cells were cultured
for 1–4 d at 37
 
8
 
C in 96-well plates in the absence or presence of
1 
 
m
 
g/ml anti-CD3, anti-TCR (BMA031; Immunotech), or PHA
and 20 U/ml recombinant human IL-2. For B cell stimulation,
PBMCs were cultured in the presence of SAC (1:10
 
4
 
 vol/vol).
 
3
 
H-labeled thymidine (1 
 
m
 
Ci/well) was added during the last 6 h
for each time point. Cells were harvested, and DNA-associated ra-
dioactivity was counted by liquid scintillation (Betaplate™; Wallac)
and expressed as a mean cpm 
 
6
 
 
 
SEM of triplicate cultures.
 
Flow Cytometry. 
 
Cell staining for T cell activation markers
was performed on PBMCs activated as described for 4 d, and us-
ing anti-CD69, anti-CD25 (Becton Dickinson), or anti–HLA-
DR (Caltag Laboratories) antibodies. Cell sorting was performed
after 4 d of stimulation with 1 
 
m
 
g/ml anti-CD3 and 20 U/ml IL-2,
using PBMCs stained with annexin V (AV)-FITC (BIODESIGN
International). Living (AV
 
2
 
) and dying or dead cells (AV
 
1
 
) were
sorted using a FACStar™ (Becton Dickinson) after gating on lym-
phocytes on the basis of forward/side scatter. Purified lympho-
cyte subsets from treated PBMCs were obtained by cell sorting
after staining with anti-CD4, anti-CD8, anti-CD19 (Becton
Dickinson), or anti-CD45RO and anti-CD45RA (Serotec Ltd.)
antibodies. For T cell subset sorting, dead cells were gated out on
the basis of forward/side scatter, and the purity of sorted T cell
subsets was 
 
.
 
99%. For each sample, 10
 
4
 
 events were collected
using the FACScan™
 
 
 
flow cytometer.
Staining for in vivo caspase activity was performed using the
cell-permeable substrate Phiphilux-G
 
1
 
D
 
2
 
 (OncoImmunin, Inc.)
containing the consensus sequence DEVDG. In brief, resting or
activated cells were washed, then incubated with the substrate
(10 
 
m
 
M final) for 1 h at 37
 
8
 
C, followed by another wash with the
dilution buffer, according to the manufacturer’s instructions. Fluo-
rescence was monitored using the FL1 detector of an EPICS
 
®
 
 XL
flow cytometer (Coulter Corp.), and gates were set on living and
either resting or blastic cells before analysis. For each sample, 3 
 
3
 
10
 
4
 
 events were collected.
 
Western Blotting. 
 
Treated cells were washed with PBS, and
pellets were resuspended in sample buffer (62.5 mM Tris-HCl,
pH 6.8, 6 M urea, 10% glycerol, 2% SDS, 0.00125% bromophe-
nol, 5% 2-ME) and boiled for 3 min. Proteins from 0.5–1 
 
3
 
 10
 
6
 
cells were separated on SDS-PAGE and transferred to nitrocellu-
lose membrane (Hybond C Super; Amersham). Blots were blocked
for 1 h at room temperature in PBS, 0.05% Tween, containing
5% nonfat dried milk, washed, and incubated with the different
antibodies. Detection was achieved with the appropriate second-
ary antibodies coupled to horseradish peroxidase (HRP), fol-
lowed by enhanced chemiluminescence ECL Western blotting
kit (NEN), and visualized by autoradiography.
 
Immunoprecipitation and Affinity Blot. 
 
Proteins from PBMCs
(5 
 
3
 
 10
 
6
 
 cells), stimulated with 1 
 
m
 
g/ml PHA and 20 U/ml IL-2
for 4 d, were extracted in lysis buffer (2% NP-40, 0.5% deoxy-
cholic acid, 50 mM Tris, pH 7.5, 150 mM NaCl, 50 mM NaF,
10 mM NaH
 
2
 
PO
 
4
 
, 2 mM EGTA, 10 mM EDTA, 0.5 mM 
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3
 
VO
 
4
 
). Cell lysates were incubated with 5 
 
m
 
M of biotinylated
zVAD-fmk and subjected or not to immunoprecipitation using
the caspase-3 antiserum. Protein G–Sepharose-coupled beads
(Amersham Pharmacia Biotech) were preincubated for 30 min at
4
 
8
 
C with 10 
 
m
 
l of anti–caspase-3 antiserum. After three washes
with lysis buffer, the beads were added to total cell lysates for a 2-h
incubation at 4
 
8
 
C with gentle agitation. The beads were then
washed three times with lysis buffer and boiled for 5 min in 50 
 
m
 
l
of Laemmli buffer. Whole cell lysates or immunoprecipitated
proteins were loaded on polyacrylamide gels for electrophoresis
and transferred to Hybond C membranes. Blots were blocked
overnight at 4
 
8
 
C with PBS, Tween 0.05% supplemented with
BSA (3%) and nonfat dry milk (2%), and revealed after incubation
with HRP-conjugated extravidin (Extra-HRP, 1:2,000; Sigma
Chemical Co.) for 1 h at room temperature for affinity blot, or
with anti–caspase-3 antiserum for Western blot as described above.
 
Fas Treatment.
 
Jurkat cells or PBMCs stimulated for 4 d with
anti-CD3 antibody and IL-2 were incubated at 10
 
6
 
 cells/well in
24-well plates coated or not with anti-Fas (M3) mAb. Coating was
performed for 2 h at 37
 
8
 
C using 20 
 
m
 
g/ml of antibody in 0.05 M
Tris, pH 9.3. After 4 h (Jurkat cells) or 6 h (PBMCs) of incubation
on coated plates, cells were washed with PBS, and the pellet was
kept at 
 
2
 
80
 
8
 
C until Western blot analysis. An aliquot of stimulated
cells was used for AV staining as described previously (11).
 
Results
 
The Caspase Inhibitor zVAD Blocks Anti-CD3–induced T
Cell Activation. 
 
Several reports have demonstrated a costim-
ulatory function of TNF receptor (TNFR) family members,
such as Fas and TNFR, which are also associated with apop-
tosis through activation of the caspase cascade (25–27).
Whether caspases play a role in the costimulatory function of
TNFR family members has yet to be demonstrated, although
caspase-3 processing has been reported after T cell stimulation
(17). To determine whether caspase-3 activation was in-
volved in the response to TCR triggering, we used the broad
spectrum caspase inhibitor zVAD (4, 5, 11, 28). Stimulation
of PBMCs with anti-CD3 antibody and IL-2 in the presence
of zVAD resulted in a dose-dependent and reproducible inhi-
bition of T cell proliferation (76.3 
 
6 
 
7.7% inhibition at day 4
with 100 
 
m
 
M of zVAD,
 
 n 
 
5 
 
8 [Fig. 1 A]) and a 2.6-fold de-
crease in the percentage of cells in S phase after 4 d of stimu-
lation, as assessed by DNA content analysis using propidium
iodide (PI) staining (data not shown). Similar results were ob-
tained using zIETD, an inhibitor of caspase-8–like members,
or the caspase-3–like protease inhibitor zDEVD (inhibition of
 
.
 
50% of the proliferation with 100 
 
m
 
M in three independent
experiments; data not shown).
To exclude the possibility that zVAD exerts a general
cytostatic effect, the caspase inhibitor was added at 1–3 d
after stimulation of PBMCs, and DNA synthesis was as-
sessed after 4 d of culture. Inhibition of T cell proliferation
by zVAD was much less significant when added 2 or 3 d af-
ter T cell activation (Fig. 1 B), indicating that it did not in-
hibit a component of the cell cycle machinery, and was not
endowed with a nonspecific cytostatic activity. A toxic ef-
fect of zVAD was also excluded, since after 4 d of stimula-
tion, zVAD could block up to 73% of the proliferation
without affecting cell viability, as assessed at day 2 or 4 by
 
AV/PI staining (% AV
 
2
 
 cells was 56.7% with zVAD vs. 57.3%
in the absence of zVAD). On the contrary, in the same exper-
iment the serine protease inhibitor 
 
N
 
-
 
p
 
-tosyl-
 
l
 
-lysine chloro-
methyl ketone (TLCK) also blocked DNA synthesis, but in-
duced a high level of cell death (up to 90% AV
 
1
 
 cells; data
not shown). Anti-CD3–induced blastic transformation was
also abolished by zVAD, as assessed by light scatter proper-
ties in flow cytometry (Fig. 1 C), confirming that inhibi-
tion of caspase activity blocked an early and critical step of
T cell activation. Addition of zVAD also resulted in the ac-
cumulation of cells expressing the early and transient acti-
vation marker CD69, whereas surface expression of the late
activation marker HLA-DR was inhibited (Fig. 1 D). In-
duction of CD25 (the 
 
a 
 
chain of the high-affinity IL-2 re-
ceptor) and CD95 upregulation remained comparable in
the presence or absence of zVAD (Fig. 1 D, and data not
shown). Since an excess of IL-2 is added at the onset of T
cell activation, and since the expression of CD25 is main-
tained in the presence of zVAD, it appears that the caspase
inhibitor does not block T cell proliferation by interfering
with the IL-2–IL-2R autocrine loop. As illustrated in Fig.
1 D, the lack of effect of zVAD on the de novo expression
of CD69 and CD25, and the fact that Jurkat cell prolifera-
tion was not affected by addition of zVAD (data not shown)
further confirm that zVAD effect on T cell proliferation
cannot be attributed to a general cytostatic effect.
Engagement of CD3 on PBMCs induces the production
of cytokines by monocytes such as IL-1
 
b
 
 and IFN-
 
g
 
 in-
ducible factor (IGIF)/IL-18, which in turn will enhance T
cell activation (29, 30). Since production of these cytokines
is dependent on caspase-1 (ICE) activity (31, 32), inhibi-
tion of T cell proliferation by zVAD could be due to a
lower level of costimulatory cytokines produced by mono-
cytes. To exclude this possibility, purified T cells (
 
.
 
95%
TCR
 
1
 
) were stimulated with anti-CD3 and IL-2 in the
presence of zVAD. Proliferation of these T cells triggered
by anti-CD3 and IL-2 was also blocked by the caspase in-
hibitor (Fig. 1 E), confirming that zVAD was directly in-
hibiting T cell activation, and not accessory cell function.
Taken together, these results show that inhibition of
caspase activity resulted in defective T cell activation and im-
paired proliferation after TCR triggering of resting T cells.
 
Early Processing of Caspase-3 during Activation of Resting Lym-
phocytes. 
 
To rule out the possibility that caspase-3 process-
ing induced by TCR triggering resulted from a lysis artifact
(19), anti-CD3–activated PBMCs were boiled directly in
Laemmli buffer containing 2% SDS, 5% mercaptoethanol,
and 8 M urea, and cell lysates were subjected to Western blot
analysis. Even under these denaturing conditions, caspase-3
proenzyme was reproducibly found (
 
n
 
 5 
 
10) completely pro-
cessed into protein species ranging from 24 to 17 kD after
TCR triggering of PBMCs (Fig. 2). These species included
the 17-kD form previously associated to the induction of ap-
optosis (2–5) and a doublet migrating at 
 
z
 
20 kD. Processing
of caspase-3 occurred as early as day 1 after TCR stimulation
and before the detection of DNA synthesis (Fig. 2 A). None
of these bands was observed in resting T cells. The same
caspase-3 pattern was also obtained after anti-TCR or PHA/ 
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IL-2 stimulation (data not shown), confirming previous results
(17). A role for granzyme B in the processing of caspase-3
during cell lysis was excluded by using the same denaturing
lysis buffer in all experiments.
To determine which of these bands constituted the ac-
tive enzyme, their ability to bind to a peptidic substrate was
assessed by affinity blot. The affinity blot technique takes
advantage of the ability of peptides mimicking caspase sub-
strates to bind irreversibly to the active caspases, but not to
their precursors (33). Fresh PBMCs were stimulated for 4 d
with anti-CD3, anti-TCR antibody, or PHA in the presence
of IL-2, and cell lysates were incubated with a biotinylated
zVAD peptide. Proteins were separated by SDS-PAGE,
and the blot was probed using Extra-HRP. Three forms
ranging from 17 to 21 kD were detected in lysates of acti-
vated, but not resting cells (Fig. 2 C). To verify whether
these proteins originated from caspase-3, the caspase was im-
munoprecipitated from lysates of PHA-stimulated PBMCs
using the antiserum, and whole lysates or immunoprecipi-
tated proteins were separated on SDS-PAGE. Western blot
analysis (Fig. 2 D, left) shows that the immunoprecipitate
contained a doublet at 20 kD, as well as the 17-kD subunit
and a 15-kD band sometimes observed in late apoptotic Jur-
kat cells using this antiserum (data not shown). When the
membrane was probed with Extra-HRP, only the 17-kD
band and the upper band from the doublet were detected
(Fig. 2 D, right), showing that both caspase-3 forms were
able to bind to the synthetic substrate.
Activation of caspase-3 was also assessed in intact cells
using the cell-permeable caspase substrate Phiphilux, con-
taining the caspase-3 consensus sequence GDEVDGI (34).
Fluorescence of resting or stimulated PBMCs was compared
Figure 1. The general caspase inhibitor
zVAD blocks anti-CD3–induced T cell acti-
vation. (A) Inhibition of PBMC proliferation
by zVAD. Purified PBMCs were cultured in
medium alone (NS) or stimulated with 1 mg/
ml anti-CD3 and 20 U/ml IL-2 (CD3) in
the presence of the indicated concentration
of zVAD. At each time point, 1 mCi/well of
[3H]thymidine was added for the last 6 h of
culture, cells were harvested, and incorpo-
rated thymidine was counted by liquid scin-
tillation. [3H]Thymidine ([3H]-TdR) incor-
poration is expressed as mean cpm 6 SEM of
triplicate cultures. Results are representative
of three experiments where full kinetics was
carried out. (B) zVAD does not inhibit cell
cycle machinery. Fresh PBMCs were placed
in RPMI medium, and 100 mM of zVAD
was added 1 h before or 1, 2, or 3 d after
stimulation in the presence of anti-CD3 anti-
body and IL-2. Cells were cultured for 4 d at
378C, and [3H]thymidine was added for the
last 6 h of incubation. Thymidine incorpora-
tion at day 4 is expressed as cpm 6 SEM
from triplicate cultures. Two independent
experiments gave similar results. (C) Inhibi-
tion of blastic transformation by zVAD.
Change in PBMCs morphology was moni-
tored by flow cytometric analysis of cellular
forward (y-axis) and side (x-axis) scatter. Per-
centage of resting PBMCs (region R1) is in-
dicated inside dot plots. One representative
experiment out of five is shown. (D) zVAD
affects the expression of MHC class II. Sur-
face staining was performed for CD69, HLA-
DR, and CD25 on PBMCs activated for 4 d
with anti-CD3/IL-2, in the presence or ab-
sence of 100 mM of zVAD. One representa-
tive experiment of three is shown. (E) The
effect of zVAD is independent of accessory
cells. Purified T lymphocytes isolated from
PBMCs by negative selection were preincu-
bated for 1 h in medium alone or with 100
mM zVAD, and cultured for 4 d without
stimulation (NS) or in the presence of IL-2,
anti-CD3, or both. Proliferation was assessed
by [3H]thymidine incorporation as described
in A. Results are representative of two inde-
pendent experiments. 
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by flow cytometry after staining in the presence of the sub-
strate. Fig. 2 E shows that Phiphilux was cleaved in T cells
4 d after anti-CD3 stimulation. Similar results were also
obtained as early as 2 d of stimulation, in which a 4.7-fold
increase in mean fluorescence intensity was observed (mean
fluorescence intensity of 27.3 vs. 5.8 for resting cells). Inter-
estingly, induction of apoptosis by anti-Fas antibody did
not result in increased Phiphilux cleavage in activated PBMCs
(Fig. 2 E), suggesting that caspase activity was already ele-
vated in proliferating cells. Therefore, caspase-3 cleavage in
stimulated lymphocytes corresponded to activation of the
proenzyme.
The complex pattern of caspase-3 subunits suggested that
they could originate from several proenzyme species ob-
served in nonstimulated cells (Fig. 2 B), or from different
cell subsets. To distinguish between these two possibilities,
sorting of CD4
 
1
 
, CD8
 
1
 
, CD45RO
 
1
 
, and CD45RA
 
1
 
 cells
was performed on viable, blastic cells. Processing of caspase-3
was similar in both CD4 and CD8 T cell subsets and oc-
curred not only in CD45RO
 
1
 
, but also in the remaining
CD45RA
 
1
 
/CD25
 
1
 
 cells (Fig. 3, A and B), further confirm-
ing that caspase activation was an early event after TCR trig-
gering. When PBMCs were stimulated for 4 d with the B
cell mitogen SAC, and B lymphocytes were purified by
CD19
 
1
 
 cell sorting, caspase-3 cleavage was observed in
sorted, viable cells and resulted in the production of the
20-kD doublet and the 17-kD large subunit as in acti-
vated T lymphocytes (Fig. 3 C). These results indicate that
caspase-3 processing occurs in several T cell subsets and in
activated B cells.
 
Selective Activation of the Caspase Cascade after TCR Trig-
gering. 
 
Having confirmed caspase-3 activation in stimu-
lated T lymphocytes, we next considered whether other
caspases could also be activated under the same conditions.
Western blot analysis was performed on lysates of unstimu-
lated or activated PBMCs, using a panel of antibodies rec-
ognizing several caspases. Fig. 4 A shows that caspase-6 and
caspase-7 were also cleaved into their active subunits after
TCR triggering. A decrease in levels of both proenzymes
(p34 for caspase-6 and p35 for caspase-7) already occurred
after 24 h of stimulation, and their cleaved subunits (p20
and p17) were clearly detected 24 h later. However, caspase
processing was selective since caspase-1, caspase-2, and
caspase-4 remained as proenzymes under these same condi-
tions (Fig. 4 B). These results further exclude a role for
granzyme B since one of its substrates, caspase-2 (35), re-
mained as a proenzyme in activated cell lysates.
 
Processing of Effector Caspases Results from the Activation of
Caspase-8. 
 
Activation of the downstream caspases during
apoptosis is usually triggered by either caspase-8 (associated
to the cytoplasmic tail of death receptors) or caspase-9 (ac-
tivated through cytochrome c release from mitochondria),
depending on the apoptotic stimulus (36–39). To identify
the pathway involved in caspase-3, -6, and -7 activation dur-
ing T lymphocyte stimulation, Western blot analysis was
performed using antibodies against caspase-8 or caspase-9.
Fig. 5 shows that after stimulation of PBMCs, caspase-8 was
fragmented into a 43–45-kD doublet corresponding to the
large subunit of caspase-8 linked to the propeptide (40),
whereas the 18-kD large subunit was detected only at day 3
Figure 2. Caspase-3 is cleaved
into multiple fragments in stimu-
lated lymphocytes. (A) Prolifera-
tion. Purified PBMCs were ob-
tained through Ficoll gradient
separation and stimulated with 1
mg/ml of anti-CD3 and 20 U/ml
of IL-2 (Anti-CD3) or not (Me-
dium). After 1–4 d at 378C, thy-
midine incorporation was deter-
mined as in the legend to Fig. 1.
(B) Caspase-3 Western blot. Pro-
teins were extracted from the
same PBMCs treated in A by cell
lysis using a denaturing Laemmli
buffer containing 8 M urea. Total
proteins extracted from 106 fresh
(d0), unstimulated (2), or stimu-
lated cells (1) were separated on
SDS-PAGE, and Western blot
analysis was performed using a
polyclonal rabbit anti–caspase-3
(reference 5). (C) Detection of
active caspases by affinity blot.
PBMCs stimulated or not for 4 d
with anti-CD3, anti-TCR, or PHA in the presence of IL-2 were lysed using a nondenaturing lysis buffer (see Materials and Methods), and lysates were
incubated with 5 mM of a biotinylated zVAD peptide, followed by a separation by SDS-PAGE and Western blot analysis using Extra-HRP. (D) Identi-
fication of active subunits of caspase-3. PBMCs were activated for 4 d with PHA and IL-2, and cell lysates were incubated with the substrate. Caspase-3
immunoprecipitation was then performed on half of the lysate. Total extract (Lys) or immunoprecipitated caspase-3 (IP) was subjected to Western blot
analysis using the anti–caspase-3 antibody (left, WB cas-3) or with Extra-HRP (right, Affinity blot). Results are from one of at least three independent
experiments giving similar results. (E) Detection of caspase activity in intact cells. Fresh PBMCs were left untreated (NS) or stimulated (CD3/IL-2) with
anti-CD3 antibody and IL-2 for 4 d. A fraction of these activated cells was then incubated for 6 h in anti-Fas–coated plates (CD3/Fas). After a 1-h label-
ing with the cell-permeable substrate Phiphilux, the cells were analyzed by flow cytometry. Results are from one representative experiment out of three.1884 Caspase Processing during T Cell Response
(observed in at least three independent experiments), when
levels of DNA synthesis were already high (Fig. 1 A and
Fig. 2). This result was confirmed using another anti–caspase-8
serum also specific for the p18 (data not shown). In the
same extracts, caspase-9, which was upregulated after TCR
triggering, remained as a proenzyme (Fig. 5 B), whereas
caspase-8 and -3 were processed as early as 16 h after T cell
activation. Therefore, these results suggest that caspase-8–
mediated processing of the downstream caspases was trig-
gered through upregulation of death receptor ligands and
FADD recruitment after T cell activation.
Caspase Substrate Specificity in Activated Lymphocytes.  Since
several downstream caspases were activated after TCR trig-
gering, we next determined whether caspase substrates
were processed in stimulated lymphocytes. PARP was the
first caspase-3 substrate identified during apoptosis (2, 9).
Stimulation with anti-CD3 and IL-2 increased PARP pro-
tein levels within 24 h (Fig. 6), confirming previous reports
showing an upregulation of PARP message and activity af-
ter PHA stimulation of primary T lymphocytes (41, 42).
Concomitant with its induction, .90% of PARP protein
was found cleaved in activated cell lysates (Fig. 6, and see
Fig. 8). PARP fragment comigrated in the same gel with
the 85-kD form found in apoptotic Jurkat cell extracts, fur-
ther confirming that caspase activity was induced after pri-
mary T cell activation. Another recently identified caspase
substrate, the Cdc2 tyrosine kinase Wee1 (13), was also up-
regulated in stimulated PBMCs (Fig. 6). Interestingly, the
97-kD full-length Wee1 that appeared 48 h after stimulation
was always detected along with 65-, 34-, and 32-kD bands
that result from caspase-mediated cleavage during Fas-medi-
ated apoptosis in Jurkat cells (Fig. 6; reference 13). There-
fore, two caspase substrates, PARP and Wee1, were pro-
cessed in activated T cells in a pattern expected from their
cleavage by caspases.
Caspase-mediated cleavage of substrates such as DFF45
or RFC140 in activated T lymphocytes would not be com-
patible with the maintenance of DNA integrity and the
proliferation of T cells, since they play a critical role in
DNA fragmentation and DNA synthesis, respectively. Thus,
it was of interest to determine whether caspase activation in
stimulated lymphocytes resulted in cleavage of these sub-
strates. The same extracts analyzed for PARP and Wee1
cleavage were subjected to Western blot analysis using an
anti-DFF45 antiserum generated against the full-length
DFF45. Results shown in Fig. 6 demonstrate that DFF45
was not cleaved in these lysates, although caspase-3 was al-
Figure 3. Caspase-3 activation occurs in various lymphocyte subsets. (A and B) Caspase cleavage is detected in CD41, CD81, CD45RO1, or
CD45RA1 lymphocytes. PBMCs were stimulated (1) or not (2) with anti-CD3 and IL-2 for 4 d at 378C, and stained for CD4, CD8, CD45RO, or
CD45RA expression. Each subset was sorted by flow cytometry after gating on living cells on the basis of forward/side scatter. The purity of sorted cells
was .99%. Total population (Tot) or sorted cells were then lysed as in the legend to Fig. 3, and subjected to Western blot analysis for caspase-3 process-
ing. (C) Caspase-3 is cleaved after B cell receptor triggering. Fresh PBMCs (To) were cultured with medium alone (NS), anti-CD3 and IL-2 (CD3), or
SAC for 4 d, and whole PBMCs (lane 1–3) or sorted CD191 B lymphocytes (lane 4) were lysed in Laemmli buffer and subjected to Western blot analysis
using the anti–caspase-3 antibody. After cell sorting, viability was .95% as assessed by trypan blue exclusion. These results are representative of four (A
and B) and two (C) independent experiments with PBMCs from different individuals.
Figure 4. Selective downstream caspase processing in activated lym-
phocytes. (A) Caspase-6 and -7 are also processed after TCR triggering.
PBMCs were stimulated (1) or not (2) with anti-CD3 antibody and IL-2
for 1–4 d, and total proteins from 106 cells were separated by SDS-PAGE
and analyzed by Western blot using anti–caspase-6 or -7 antisera. The
proenzymes and cleaved subunits are indicated on the right by arrows. (B)
All caspases are not processed in activated cells. Day 4 unstimulated (2)
or anti-CD3/IL-2 stimulated (1) PBMCs were analyzed for caspase-1, -2,
or -4 processing by Western blot, as in A.1885 Alam et al.
most completely processed (Fig. 6). The cleavage of RFC140
was analyzed by Western blot, and results confirmed that
this substrate was also resistant to caspase-mediated cleavage
in activated lymphocytes, as we have observed previously
(11; data not shown).
To ensure that Wee1 and PARP cleavage resulted from
caspase activity, fresh PBMCs were stimulated with anti-
CD3 antibody and IL-2 in the absence or presence of 100 mM
of zVAD. Western blot analysis of cell lysates shows that
Wee1 cleavage to a 60-kD fragment and the appearance of
the 85-kD form of PARP were both inhibited by zVAD
(Fig. 7 A). Interestingly, addition of zVAD, which inhib-
ited T cell proliferation, also reduced caspase-3 processing
(Fig. 7 A), further supporting a correlation between caspase-3
activation and cell cycle entry. The caspase-6 substrate
lamin B (7) was also analyzed by Western blot in lysates of
activated lymphocytes, and a zVAD-sensitive cleavage gen-
erating a 28- and a 35-kD fragment was observed in stimu-
lated cells (Fig. 7 A), further confirming that caspase-6 was
active in these cells. As published previously, cleavage of
RFC140 was detectable in activated PBMCs only after
anti-Fas treatment (11). To ensure that this was also the
case for DFF45, anti-CD3–stimulated PBMCs were incu-
bated for 6 h on anti-Fas–coated plates at 378C and sub-
jected to Western blot analysis using anti-DFF45 antiserum.
This treatment resulted in a decrease of living, AV2 cells
from 65 to 20% (Fig. 7 B). Western blot analysis demon-
strated that the 14-kD fragment of DFF45 was only
detectable in lysates of apoptotic cells. Therefore, caspase
activity observed in proliferating T cells resulted in selec-
tive substrate specificity, different from the one observed
during T cell apoptosis.
Caspase and Substrate Cleavage Occur in Proliferating and
Nonapoptotic Cells. To rule out a potential contribution of
dying cells for cleaved forms of caspases or for their sub-
strates, Western blot analysis was performed on highly pu-
rified living cells. PBMCs were stimulated for 4 d using
anti-CD3 antibody in the presence of IL-2, and stained
with AV-FITC. Purified living (AV2) or dying (AV1) cells
were obtained by flow cytometric cell sorting. The sorted
populations were restained with AV to ensure that sorting
did not affect cell viability, and .92% of the cells were
found to be AV2. Lysates of sorted cells were subjected to
caspase-3 or PARP Western blot analysis. Results show
that all of the processed forms of caspase-3, as well as the
85-kD fragment of PARP, were present in AV2 cells (Fig.
8 A), further confirming that the presence of caspase-3
cleavage products was not due to contamination with dead
cells. In nonapoptotic sorted cells, the caspase-3 substrate
PARP was almost completely cleaved, showing that
Figure 5. Caspase-8 is cleaved in activated lymphocytes, whereas
caspase-9 remains as a proenzyme. (A) Caspase-8 is processed in prolifer-
ating cells. PBMCs were stimulated (1) or not (2) with anti-CD3 anti-
body and IL-2 for 1–4 d, and total proteins from 106 cells were analyzed
by Western blot using an anti–caspase-8 antiserum. The proenzyme and
cleaved subunits are indicated on the right by arrows. (B) Caspase-8, but
not caspase-9, is activated early after T cell stimulation. Fresh (0) or anti-
CD3–stimulated PBMCs (1–48 h) were lysed, and 10 mg of proteins from
each sample was separated by SDS-PAGE and analyzed for caspase-3, -8,
and -9 processing by Western blot, as described above. Results are repre-
sentative of two independent experiments.
Figure 6. Caspase activation results in selective substrate cleavage. Total
proteins from 106 unstimulated (2) or anti-CD3–activated (1) PBMCs
were obtained at different time points (day 1 to day 4), separated by SDS-
PAGE, and analyzed by Western blot using an anti-PARP, DFF45, or
caspase-3 antiserum, or an anti-Wee1 mAb. As a control for caspase-
mediated cleavage, total proteins from 106 Jurkat cells cultured on un-
coated or anti-Fas–coated plates (M3: 20 mg/ml) for 4 h were subjected to
the same treatment as PBMCs, and results are shown on the right. The
45-kD strong band observed with the anti-Wee1 antibody throughout the
kinetic results from a cross-reactivity observed in some tissues with this an-
tibody, according to the manufacturer. These experiments were performed
three times, and gave similar results with different PBMC donors.1886 Caspase Processing during T Cell Response
caspase-3 processing correlated with caspase activity. Strik-
ingly, caspase-3–processed forms were almost absent in ly-
sates of apoptotic (AV1) cells, suggesting that their half-life
could be very short. Confirming this hypothesis, we have
observed that caspase-3–cleaved forms progressively disap-
pear from activated lymphocytes after IL-2 withdrawal,
concomitant with an increase in mortality (up to 70%; data
not shown).
To ensure that cleavage of other caspases or substrates
also occurred in nonapoptotic cells, PBMCs stimulated for
2 d (to further limit the proportion of apoptotic cells) with
anti-CD3 antibody were stained with AV-FITC, and after
gating on blasts, AV2 cells were sorted by flow cytometry.
Extracts from 5 3 105 cells were prepared from resting, un-
sorted PBMCs or activated, AV2 sorted cells, and proteins
were analyzed by Western blot using antibodies against
caspase-6, caspase-7, PARP, and Wee1. As a control for
dead cell contamination, these extracts were also analyzed
for DFF45 cleavage. Fig. 8 B shows that both caspases, as
well as PARP and DFF45, were not cleaved in resting cells
(lane 1), whereas Wee1 was not detected. After TCR
cross-linking, caspase-6– and caspase-7–cleaved subunits
were detected in AV2 sorted cells (lane 2), as well as the
PARP 85-kD cleaved form and the 66-, 32-, and 34-kD
fragments of Wee1. In these extracts, DFF45 was not pro-
cessed, excluding a potential contamination by dead cells.
Altogether, these results clearly indicate that a selective
caspase substrate cleavage occurs in viable T lymphocytes
activated through the TCR.
Discussion
Results presented in this report show that caspase activa-
tion after TCR triggering is a physiological, tightly regu-
lated, and early response that appears to be required for ef-
ficient T cell activation. Indeed, the selective processing of
caspase-3, -6, -7, and -8 was detected within 24 h after
anti-CD3 stimulation of peripheral blood lymphocytes.
Caspase processing occurred in various T and B cell sub-
sets, and was found in proliferating and nonapoptotic lym-
phocytes. Activation of caspases was confirmed through
binding of caspase-3–processed forms to a specific substrate,
and by showing that a cell-permeable substrate was cleaved
in intact, activated lymphocytes. Importantly, activation of
the caspase cascade was associated to restricted substrate
specificity, with cleavage of PARP and Wee1 being ob-
served while two other substrates, DFF45 and RFC140,
remained unaffected. Caspase processing after T cell stimu-
lation correlated with a defective lymphocyte activation in
the presence of the caspase inhibitor zVAD, suggesting that
caspase activity could be involved in some early steps of
lymphocyte activation.
Death receptors such as TNFR and Fas can act as co-
stimulatory molecules and enhance T cell proliferation
(25–27). We have also observed that a soluble form of
TNFR significantly inhibited T cell proliferation induced
by anti-CD3 antibody (our unpublished results). Cross-
linking of these death receptors triggers the FADD-depen-
dent recruitment of caspase-8, which is processed and can
directly mediate the activation of caspase-3, -6, and -7 by
Figure 7. Substrate process-
ing during T cell activation is
caspase dependent and is dif-
ferent than after apoptosis. (A)
Substrate cleavage is caspase de-
pendent. Fresh PBMCs were
stimulated for 48 h with anti-
CD3 and IL-2 in the presence or
absence of 100 mM of zVAD.
An aliquot was conserved for
quantitation of DNA synthesis
by thymidine incorporation, and
cells were lysed in denaturing
buffer for Western blot analysis
of PARP, Wee1, lamin B, and
caspase-3 cleavage. Black arrows
indicate the full-length proteins,
and white arrows designate the
cleaved forms. (B) DFF45 cleavage
is detected only after apoptosis
induction. PBMCs activated for
4 d with anti-CD3 and IL-2
were placed in anti-Fas–coated
plates and cultured for 6 h at
378C. Apoptosis was assessed by
AV/PI staining, and the cells
were subjected to Western blot
analysis using the DFF45 antise-
rum. Results are from one repre-
sentative experiment out of three.1887 Alam et al.
proteolytic cleavage (36, 37). Our results show that caspase-8
is processed after T cell stimulation (as early as 16 h after
TCR cross-linking), and activates caspase-3, -6, and –7,
leading to a selective cleavage of their substrates. Interest-
ingly, addition of the caspase-8 inhibitor zIETD during T
cell stimulation inhibited .60% of the proliferation (data
not shown), which further confirms that caspase-8 activity
is involved in cell cycle entry of activated lymphocytes.
The fact that activation of the whole caspase cascade occurs
in proliferating, viable (AV2) cells indicates that caspases could
be the executioners in the costimulatory function of mem-
bers of the TNFR family. In support of this hypothesis, im-
paired T cell proliferation is also observed in FADD-defi-
cient and in FADD dominant negative transgenic mice
(20–22), suggesting a potential role for caspases in the early
events leading to cell division. Caspase processing in stimu-
lated cells appears to be mediated mostly through the acti-
vation of caspase-8 associated to death receptor. The other
pathway of downstream caspase activation involves caspase-9,
which is triggered after the release in the cytosol of mito-
chondrial cytochrome c (38, 39). However, we have found
that in stimulated T cells this caspase remains as a proenzyme.
Bcl-2 and other antiapoptotic members of the family
have been shown to block caspase activation after several
apoptotic stimuli (43). However, Bcl-2 is also endowed
with the ability to influence cell cycle progression. Indeed,
Bcl-2 overexpression in transgenic mice was reported to
decrease cell cycle entry of primary lymphocytes (23). Trans-
fection of Bcl-2 into NIH 3T3 cells also delayed their reen-
try into cell cycle after serum withdrawal, and a tyrosine 28
mutant in the NH2-terminal BH4 domain exhibited domi-
nant negative effects over the wild-type Bcl-2 (24). Whether
the effect of Bcl-2 on cell cycle progression also involves
regulation of caspase activity remains to be addressed. How-
ever, these data associated with our results showing the in-
hibitory effect of zVAD on DNA synthesis suggest that
caspases (along with their upstream regulators FADD and
Bcl-2) may be involved in cell cycle entry during lympho-
cyte activation.
Results presented in this study clearly demonstrate a se-
lective processing of caspase substrates. PARP, which is in-
volved in DNA repair (44), is probably processed in apop-
totic cells to allow for DNA fragmentation after DFF45
cleavage. Of note, PARP expression and activity increase
after T cell stimulation (41). Therefore, the 85-kD frag-
ment of PARP probably conserves an enzymatic activity
that mediates an unknown function in proliferating cells.
Our results also demonstrate the selective processing of
Wee1. This tyrosine kinase is a negative regulator of Cdc2
(45), a cyclin-dependent kinase required for the G2/M
transition during cell cycle, as well as for Fas-mediated apop-
tosis in immortalized cell lines (13). Wee1 is a critical
component of the G2/M cell cycle checkpoint machinery,
and mediates cell cycle arrest after DNA damage by phos-
phorylation of Cdc2 (45). Therefore, cleavage of Wee1 in
proliferating lymphocytes could lead to its inactivation,
thus allowing cell cycle progression. Of note, Wee1 pro-
cessing by caspases during apoptosis in Jurkat cells correlates
with a 20-fold decrease in Wee1 activity and an increase in
Cdc2 activity (13). The nuclear protein lamin B is consid-
ered as a caspase-6 substrate (7). Our results show that in
fresh PBMCs, two forms of 66 and 45 kD can be identified
by Western blot using an anti–lamin B antibody, and at
least two fragments of 35 and 28 kD are produced after T
cell activation. Appearance of these products correlates
with a decrease in the amount of the 45-kD form of lamin
B, and is inhibited by addition of zVAD (Fig. 7 A). Al-
though the significance of this cleavage in activated lym-
phocytes is unclear, it confirms the activation of caspase-6,
which generates the 28-kD fragment after a cleavage at the
consensus sequence VEID (7).
In our experiments, DFF45 is present in resting as well as
in proliferating cells, whereas RFC140 is upregulated after
T cell stimulation. Since caspase-mediated DFF45 process-
ing leads to DNA fragmentation, one could easily predict
that it would not be cleaved in activated living cells. In-
deed, we were unable to detect DFF45 cleavage in AV2
Figure 8. Caspase and substrate cleavage occur in nonapoptotic cells.
(A) Caspase-3 and PARP processing are detected in AV2 cells. PBMCs
were stimulated (1) or not (2) with anti-CD3 antibody and IL-2 for 4 d,
and stained for 10 min with FITC-conjugated AV. Living (AV2) and dy-
ing (AV1) activated lymphocytes were purified by flow cytometric cell
sorting. Proteins from sorted cells were subjected to Western blot analysis
for caspase-3 and PARP. Both antibodies were used on the same mem-
brane. One representative experiment of three is shown. (B) Caspase-6
and -7 and the caspase substrates are processed in viable sorted cells. Un-
stimulated and unsorted PBMCs (lane 1) or activated and AV2 sorted
cells (lane 2) were lysed in Laemmli buffer. Proteins from 5 3 105 cells
were analyzed by Western blot for PARP, DFF45, Wee1, caspase-6, or
caspase-7 processing using the appropriate antisera. Arrows on the right
indicate the full-length form of each protein. Results are representative of
two independent experiments.1888 Caspase Processing during T Cell Response
cells after T cell activation, although the 14-kD fragment
generated by caspase-3 cleavage at the second site was ob-
served in lysate from activated lymphocytes after anti-Fas
treatment. The lack of RFC140 cleavage in proliferating T
cells was also critical, since processing of RFC140 by caspases
leads to inactivation of the DNA replication machinery and
cell cycle arrest at the G2/M boundary (11). This selective
substrate processing could explain why T lymphocytes survive
and proliferate although the caspase cascade including cas-
pase-8, -3, -6, and -7 is activated after TCR triggering. To
explain this selective caspase specificity in stimulated lym-
phocytes, several hypotheses can be proposed. Endogenous
caspase inhibitors, such as the inhibitor of apoptosis (IAP) fam-
ily members, could selectively inhibit the cleavage of specific
substrates in stimulated cells (46). Supporting this hypothesis,
the expression of thymic IAP, a murine homologue of sur-
vivin, is upregulated within 24 h of stimulation in splenic T
cells (47), and this member of the IAP family was shown to
inhibit already processed caspase-3, -7, and -9 (46). Associ-
ation of thymic IAP to caspases could have a differential effect
on the cleavage of their substrates, depending on the affinity of
the caspase for these substrates or their accessibility. Alterna-
tively, some caspase substrates involved in cell survival could
be protected against cleavage by phosphorylation near the
caspase cleavage site. This mechanism was recently demon-
strated for presenilin-2. Caspase-mediated cleavage of this
molecule was abrogated by Ser327 and Ser330 phosphorylation
inside the consensus cleavage site DSYD¯S (48).
In summary, activation of the caspase cascade in nonapop-
totic lymphocytes, together with the impairment of T cell
activation by caspase inhibitors, indicates that these pro-
teases may play an important role during T cell stimulation,
and caspases may be added to the growing list of molecules
that are involved in cell death and proliferation. However,
elucidation of the function of caspase processing in acti-
vated lymphocytes will require further experiments and
will provide new insights into the biological function of
caspases, as well as the regulation of T cell activation.
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